Systemic Sclerosis Associated Interstitial Lung Disease Ssc Ild Epidemiology Forecast Insight

DelveInsight’s ‘Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the SSc-ILD, historical and forecasted epidemiology as well as the SSc-ILD trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Disease Understanding

Systemic sclerosis (SSc), also referred to as scleroderma, is a rare chronic, multisystem connective tissue disease characterized by microangiopathy, diffuse fibrosis, and vascular abnormalities in the skin, joints, and internal organs (especially the esophagus, lower gastrointestinal tract, lungs, heart, and kidneys). SSc encompasses a spectrum of related disorders, most of which share a characteristic clinical feature of skin thickening due to an excess of collagen fibers. The classification of SSc can be done based on limited systemic sclerosis, generalized systemic sclerosis, and systemic sclerosis sine scleroderma.

 

Limited systemic sclerosis is characterized by slow progression. Patients develop skin tightening over the face and distal to the elbows and knees and are often complicated by pulmonary hypertension.

 

Generalized systemic sclerosis evolves rapidly with diffuse skin involvement. Interstitial lung disease and scleroderma renal crisis are the major complications. In systemic sclerosis sine scleroderma, patients have systemic sclerosis-related antibodies and visceral manifestations of the disease but no skin tightening.

 

Additionally, systemic sclerosis patients are sorted into two additional subgroups based on the extent of skin involvement. These subgroups are diffuse cutaneous scleroderma and limited cutaneous scleroderma.

Continued in the report…..

Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of SSc, Diagnosed Prevalent Cases of SSc, Total Prevalent Cases of SSc-ILD, Diagnosed Prevalent Cases of SSc-ILD, Gender-specific Diagnosed Prevalence of SSc-ILD, Age-specific Diagnosed Prevalence of SSc-ILD, and Severity-specific Prevalence of SSc-ILD scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018−2030.

SSc-ILD Detailed Epidemiology Segmentation

  • In 2020, the total prevalent population of SSc were found out to be 191,701 in the 7MM, these cases are expected to grow during the study period 2018–2030.
  • The estimates suggest the highest diagnosed prevalent cases of SSc in the United States with 69,070 cases in 2020.
  • The highest number, 35,916 cases of SSc-ILD were prevalent in the US in 2020 and the least number, 2,584 cases of SSc-ILD were prevalent in 2020, in Germany.
  • The total number of SSc-ILD cases in females was 24,423 and in males, it was 6,106 cases in 2020, in the US.
  • In the US, the diagnosed prevalent cases in the age group of 65+ years were the highest with 13,738 cases in 2020.
  • The prevalent cases of SSc-ILD that require treatment are further segmented based on the severity of SSc-ILD into mild, moderate, and severe. In 2020, the severity-specific estimated cases were 6,970, 14,565 and 8,993 for mild, moderate, and severe, respectively in the US.
  • Japan had 5,689 diagnosed prevalent cases of SSc-ILD in 2020.

Scope of the Report

  • The report covers the descriptive overview of SSc-ILD, explaining its causes, symptoms, pathophysiology, and genetic basis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Systemic Sclerosis-associated Interstitial Lung Disease.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of SSc, Diagnosed Prevalent Cases of SSc, Total Prevalent Cases of SSc-ILD, Diagnosed Prevalent Cases of SSc-ILD, Gender-specific Diagnosed Prevalence of SSc-ILD, Age-specific Diagnosed Prevalence of SSc-ILD, and Severity-specific Prevalence of SSc-ILD.

Report Highlights

  • 10-Year Forecast of SSc-ILD
  • 7MM Coverage
  • Total Prevalent Cases of SSc
  • Diagnosed Prevalent Cases of SSc
  • Total Prevalent Cases of SSc-ILD
  • Diagnosed Prevalent Cases of SSc-ILD
  • Gender-specific Diagnosed Prevalence of SSc-ILD
  • Age-specific Diagnosed Prevalence of SSc-ILD
  • Severity-specific Prevalence of SSc-ILD

Key Questions Answered

  • What are the disease risk, and burden of SSc-ILD?
  • What is the historical SSc-ILD patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of SSc-ILD at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to SSc-ILD?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of SSc-ILD during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM SSc-ILD epidemiology forecast.
  • The SSc-ILD epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The SSc-ILD epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Future Prospects

4. Executive Summary of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

5. Key Events

6. Systemic Sclerosis-associated Interstitial Lung Disease: Disease Background and Overview

6.1. Introduction

6.2. Signs and Symptoms

6.3. Risk Factors

6.4. Causes

6.5. Pathogenesis

6.6. Diagnostic Approach

6.6.1. Diagnostic algorithm

6.6.2. Diagnostic Recommendations

6.6.3. Biomarkers in Systemic Sclerosis-associated Interstitial Lung Disease

6.7. Treatment and Management

6.7.1. Treatment Algorithm

6.7.2. Treatment Recommendations

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Methodology

7.3. Assumptions and Rationale: 7MM

7.4. Total Prevalent Cases of SSc in the 7MM

7.5. Diagnosed Prevalent Cases of SSc in the 7MM

7.6. Total Prevalent Cases of SSc-ILD in the 7MM

7.7. Diagnosed Prevalent Cases of SSc-ILD in the 7MM

7.8. The United States

7.8.1. Total Prevalence of Systemic Sclerosis (SSc) in the United States

7.8.2. Total Diagnosed Prevalence of SSc in the United States

7.8.3. Total Prevalence of SSc-ILD in the United States

7.8.4. Total Diagnosed Prevalence of SSc-ILD in the United States

7.8.5. Gender-specific Diagnosed Prevalence of SSc-ILD in the United States

7.8.6. Age-specific Diagnosed Prevalence of SSc-ILD in the United States

7.8.7. Severity-specific Prevalence of SSc-ILD in the US

7.9. EU5

7.9.1. Total Prevalence of Systemic Sclerosis (SSc) in EU-5

7.9.2. Total Diagnosed Prevalence of SSc in EU-5

7.9.3. Total Prevalence of SSc-ILD in EU-5

7.9.4. Total Diagnosed Prevalence of SSc-ILD in EU-5

7.9.5. Gender-specific Diagnosed Prevalence of SSc-ILD in EU-5

7.9.6. Age-specific Diagnosed Prevalence of SSc-ILD in EU-5

7.9.7. Severity-specific Prevalence of SSc-ILD in the EU5

7.10. Japan

7.10.1. Total Prevalence of SSc in Japan

7.10.2. Total Diagnosed Prevalence of SSc in Japan

7.10.3. Total Prevalence of SSc-ILD in Japan

7.10.4. Total Diagnosed Prevalence of SSc-ILD in Japan

7.10.5. Gender-specific Diagnosed Prevalence of SSc-ILD in Japan

7.10.6. Age-specific Diagnosed Prevalence of SSc-ILD in Japan

7.10.7. Severity-specific Prevalence of SSc-ILD in Japan

8. Patient Journey

9. Appendix

9.1. Report Methodology

9.2. Bibliography

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of SSc-ILD Epidemiology (2018–2030)

Table 2: Key Events

Table 3: Quantitative and Semi-quantitative Scoring for SSc-ILD Through HRCT

Table 4: High-resolution Computed Tomography Advantages And Drawbacks

Table 5: Recommendations of the European Panel

Table 6: Main Biomarkers Associated With Systemic Sclerosis-associated Interstitial Lung Disease

Table 7: Main biomarkers with clinical interest for SSc-ILD

Table 8: Recommendations of the European Panel

Table 9: Total Prevalent Cases of SSc in the 7MM (2018–2030)

Table 10: Diagnosed Prevalent Cases of SSc in the 7MM (2018–2030)

Table 11: Total Prevalent Cases of SSc-ILD in the 7MM (2018–2030)

Table 12: Diagnosed Prevalent Cases of SSc-ILD in the 7MM (2018–2030)

Table 13: Total Prevalence of Systemic Sclerosis (SSc) in the United States (2018–2030)

Table 14: Total Diagnosed Prevalence of SSc in the United States (2018–2030)

Table 15: Total Prevalence of SSc-ILD in the United States (2018–2030)

Table 16: Total Diagnosed Prevalence of SSc-ILD in the United States (2018–2030)

Table 17: Gender-specific Diagnosed Prevalence of SSc-ILD in the United States (2018–2030)

Table 18: Age-specific Diagnosed Prevalence of SSc-ILD in the US (2018–2030)

Table 19: Severity-specific Prevalence of SSc-ILD in the US (2018–2030)

Table 20: Total Prevalence of Systemic Sclerosis (SSc) in EU-5 (2018–2030)

Table 21: Total Diagnosed Prevalence of SSc-ILD in EU-5 (2018–2030)

Table 22: Total Prevalence of SSc-ILD in EU-5 (2018–2030)

Table 23: Total Diagnosed Prevalence of SSc-ILD in EU-5 (2018–2030)

Table 24: Gender-specific Diagnosed Prevalence of SSc-ILD in EU-5 (2018–2030)

Table 25: Age-specific Diagnosed Prevalence of SSc-ILD in EU5 (2018–2030)

Table 26: Severity-specific Prevalence of SSc-ILD in EU5 (2018–2030)

Table 27: Total Prevalence of SSc in Japan (2018–2030)

Table 28: Total Diagnosed Prevalence of SSc in Japan (2018–2030)

Table 29: Total Prevalence of SSc-ILD in Japan (2018–2030)

Table 30: Total Diagnosed Prevalence of SSc-ILD in Japan (2018–2030)

Table 31: Gender-specific Diagnosed Prevalence of SSc-ILD in Japan (2018–2030)

Table 32: Age-specific Diagnosed Prevalence of SSc-ILD in Japan (2018–2030)

Table 33: Severity-specific Prevalence of SSc-ILD in Japan (2018–2030)

List of Figures

Figure 1: Symptoms Associated With Systemic Sclerosis-associated Interstitial Lung Disease

Figure 2: Risk Factors of Systemic Sclerosis-associated Interstitial Lung Disease

Figure 3: Causes of Systemic Sclerosis-associated Interstitial Lung Disease

Figure 4: Pathogenesis of Lung Fibrosis in Systemic Sclerosis-associated Interstitial Lung Disease

Figure 5: Diagnostic algorithm for Systemic Sclerosis-associated Interstitial Lung Disease

Figure 6: Screening and Monitoring Algorithm for Interstitial Lung Disease in Patients With Systemic Sclerosis

Figure 7: Algorithm for Remission in Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD)

Figure 8: Clinical Management Algorithm For Systemic Sclerosis-associated ILD

Figure 9: Total Prevalent Cases of SSc in the 7MM (2018–2030)

Figure 10: Diagnosed Prevalent Cases of SSc in the 7MM (2018–2030)

Figure 11: Total Prevalent Cases of SSc-ILD in the 7MM (2018–2030)

Figure 12: Diagnosed Prevalent Cases of SSc-ILD in the 7MM (2018–2030)

Figure 13: Total Prevalence of Systemic Sclerosis (SSc) in the United States (2018–2030)

Figure 14: Total Diagnosed Prevalence of SSc in the United States (2018–2030)

Figure 15: Total Prevalence of SSc-ILD in the United States (2018–2030)

Figure 16: Total Diagnosed Prevalence of SSc-ILD in the United States (2018–2030)

Figure 17: Gender-specific Diagnosed Prevalence of SSc-ILD in the United States (2018–2030)

Figure 18: Age-specific Diagnosed Prevalence of SSc-ILD in the US (2018–2030)

Figure 19: Severity-specific Prevalence of SSc-ILD in the US (2018–2030)

Figure 20: Total Prevalence of Systemic Sclerosis (SSc) in EU-5  (2018–2030)

Figure 21: Total Diagnosed Prevalence of SSc in EU-5 (2018–2030)

Figure 22: Total Prevalence of SSc-ILD in EU-5 (2018–2030)

Figure 23: Total Diagnosed Prevalence of SSc-ILD in EU-5 (2018–2030)

Figure 24: Gender-specific Diagnosed Prevalence of SSc-ILD in EU-5 (2018–2030)

Figure 25: Age-specific Diagnosed Prevalence of SSc-ILD in EU-5 (2018–2030)

Figure 26: Severity-specific Prevalence of SSc-ILD in EU5 (2018–2030)

Figure 27: Total Prevalence of SSc in Japan (2018–2030)

Figure 28: Total Diagnosed Prevalence of SSc in Japan (2018–2030)

Figure 29: Total Prevalence of SSc-ILD in Japan (2018–2030)

Figure 30: Total Diagnosed Prevalence of SSc-ILD in Japan (2018–2030)

Figure 31: Gender-specific Diagnosed Prevalence of SSc-ILD in Japan (2018–2030)

Figure 32: Age-specific Diagnosed Prevalence of SSc-ILD in Japan (2018–2030)

Figure 33: Severity-specific Prevalence of SSc-ILD in Japan (2018–2030)

Forward to Friend

Need A Quote